Humane Genomics, founded with a mission to revolutionize cancer treatment, focuses on engineering highly specific oncolytic viral therapies. Using synthetic biology, the company has developed a platform to design and test cancer-killing viruses, particularly targeting pediatric liver cancer (hepatoblastoma). Their approach leverages computer-aided design and DNA synthesis to create viruses with a high on-target to off-target kill ratio, ensuring precision in targeting cancer cells while minimizing damage to healthy cells.
Notable affiliations include partnerships with Texas Children's Hospital, a leader in pediatric care. Humane Genomics has achieved significant milestones in developing their first therapeutic indication for hepatoblastoma. The company's innovative platform and strategic collaborations position it as a pioneering force in the field of oncolytic viral therapies, potentially transforming cancer treatment paradigms and offering new hope for patients with challenging cancers.
